Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

About Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics logoPluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PSTI
  • CUSIP: N/A
  • Web:
  • Market Cap: $142.31 million
  • Outstanding Shares: 97,473,000
Average Prices:
  • 50 Day Moving Avg: $1.20
  • 200 Day Moving Avg: $1.28
  • 52 Week Range: $1.04 - $1.66
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.31 per share
  • Price / Book: 5.03
  • EBIDTA: ($25,840,000.00)
  • Return on Equity: -89.81%
  • Return on Assets: -72.46%
  • Current Ratio: 5.36%
  • Quick Ratio: 5.36%
  • Average Volume: 327,442 shs.
  • Beta: 0.1
  • Short Ratio: 5.82

Frequently Asked Questions for Pluristem Therapeutics (NASDAQ:PSTI)

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) released its earnings results on Thursday, November, 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.04. The firm earned $0.10 million during the quarter, compared to analyst estimates of $0.10 million. View Pluristem Therapeutics' Earnings History.

When will Pluristem Therapeutics make its next earnings announcement?

Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Pluristem Therapeutics.

Where is Pluristem Therapeutics' stock going? Where will Pluristem Therapeutics' stock price be in 2017?

3 equities research analysts have issued 12 month target prices for Pluristem Therapeutics' stock. Their predictions range from $2.00 to $6.00. On average, they expect Pluristem Therapeutics' stock price to reach $3.83 in the next year. View Analyst Ratings for Pluristem Therapeutics.

What are analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:

  • 1. Maxim Group analysts commented, "Summary Pluristem announced that Austria’s regulatory health agency, the Austrian Agency for Health and Food Safety (AGES), has cleared the study to begin enrollment in Austria. The PIII trial is currently enrolling patients in the U.S., U.K., and Germany. Pluristem is focused on showing the benefits of therapy in prolonging the time to an event. If patients can keep a limb a year longer, is the therapy viable and does it create value. We do believe the current statistical plan is well designed to show if a difference exists in the time to event analysis. What will be critical will be if US regulators will accept time to event in place of AFS for approval. It stands to reason that a treatment effect which prolongs time to event, (as is the standard on oncology) could suffice for approval in CLI (Critical Limb Ischemia). i.e. if the treated group keeps limbs longer, is the therapy approvable one and is there benefit? We must also consider changes in the regulatory landscape and what impact the adaptive pathway and 21st Century Act might have on regenerative medicine – cell therapy approval timelines." (7/10/2017)
  • 2. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (4/13/2017)

Who are some of Pluristem Therapeutics' key competitors?

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the folowing people:

  • Yaky Yanay, Chairman of the Board, Chief Executive Officer
  • Zalman Aberman, President, Co-Chief Executive Officer, Director
  • Erez Egozi, Chief Financial Officer
  • Doron Shorrer CPA, Lead Independent Director
  • Moria Kwiat, Director
  • Hava Meretzki, Director
  • Israel Ben-Yoram, Independent Director
  • Issac Braun, Independent Director

Who owns Pluristem Therapeutics stock?

Pluristem Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (1.04%), California Public Employees Retirement System (0.19%) and Harel Insurance Investments & Financial Services Ltd. (0.10%). Company insiders that own Pluristem Therapeutics stock include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman. View Institutional Ownership Trends for Pluristem Therapeutics.

How do I buy Pluristem Therapeutics stock?

Shares of Pluristem Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of Pluristem Therapeutics stock can currently be purchased for approximately $1.56.

MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.83 (145.73% upside)

Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017HC WainwrightReiterated RatingBuy$3.50LowView Rating Details
9/5/2017Maxim GroupReiterated RatingBuy$2.00MediumView Rating Details
1/10/2017FBR & CoReiterated RatingBuyN/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
Earnings by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Earnings History by Quarter for Pluristem Therapeutics (NASDAQ PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.08)N/AView Earnings Details
11/6/2014($0.13)($0.09)$0.10 million$0.10 millionViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)$0.10 million$0.09 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.14)$0.20 million$0.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS


Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 4.47%
Insider Trades by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Institutional Ownership by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Trades by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pluristem Therapeutics (NASDAQ:PSTI)
Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
DateHeadline logoFDA Grants Fast Track Designation To Pluristem's PLX-PAD For Treatment Of CLI - September 20 at 7:59 AM logoCorporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP - September 20 at 7:59 AM logoPluristem Therapeutics' (PSTI) Buy Rating Reaffirmed at HC Wainwright - September 19 at 3:14 PM logoPluristem Therapeutics (PSTI) Reports U.S. FDA Grants Fast Track ... - - September 19 at 6:47 AM logoPluristem Wins Key FDA Approval - September 19 at 6:47 AM logoBiotech Stocks Surging in September - September 19 at 6:47 AM logoPluristem Therapeutics (PSTI) versus Puma Biotechnology (PBYI) Head-To-Head Contrast - September 18 at 9:00 AM logoPluristem Therapeutics (PSTI) Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle ... - - September 14 at 9:34 AM logoPluristem Therapeutics Inc.: A Biotech Company Inspired By Life - Seeking Alpha - September 14 at 9:34 AM logoPluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration - September 13 at 8:02 AM logoShould You Buy Pluristem Therapeutics Inc (PSTI)? - September 12 at 8:51 AM logoPluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights - September 12 at 8:51 AM logoPluristem Therapeutics (PSTI) & Bio-Path Holdings (BPTH) Financial Review - September 8 at 10:28 PM logoHC Wainwright Reaffirms Buy Rating for Pluristem Therapeutics, Inc. (PSTI) - September 6 at 3:56 PM logoPluristem Therapeutics' (PSTI) "Buy" Rating Reiterated at Maxim Group - September 6 at 3:20 PM logo$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program - GlobeNewswire (press release) - September 6 at 7:31 AM logo$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program - September 6 at 7:31 AM logoPluristem Therapeutics, Inc. (PSTI) Set to Announce Quarterly Earnings on Monday - September 4 at 2:22 AM logoValuEngine Downgrades Pluristem Therapeutics, Inc. (PSTI) to Strong Sell - September 2 at 5:38 PM logoHealth Care Sector Update for 08/16/2017: PSTI,IDXG,JAGX - Nasdaq - August 17 at 8:27 PM logoPluristem Therapeutics (PSTI) DOD to Conduct Studies of its PLX-R18 in New ARS Project for Use Before Radiation ... - - August 17 at 3:23 PM logoHC Wainwright Reaffirms "Buy" Rating for Pluristem Therapeutics, Inc. (PSTI) - August 17 at 7:46 AM logoABIO To Report Data In Q1; IOVA Fired Up, PMD In Iowa, VRX All Cleared - August 17 at 7:05 AM logoPluristem Therapeutics (PSTI) DOD to Conduct Studies of its PLX-R18 in New ARS Project for Use Before Radiation Exposure - August 17 at 7:05 AM logoU.S. Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project for Use Before Radiation Exposure - August 17 at 7:05 AM logoThese Are the Hottest Stocks on the Planet Wednesday: URBN, TGT, PSTI, CSCO - August 17 at 7:05 AM logoPluristem Therapeutics, Inc. (PSTI) Given a $2.00 Price Target by Maxim Group Analysts - August 16 at 8:58 PM logoIsraeli Government to Support Pluristem's Marketing Activity in China – Ministry of Economy Awards Company “Smart ... - GlobeNewswire (press release) - August 10 at 7:04 AM logoIsraeli Government to Support Pluristem’s Marketing Activity in China – Ministry of Economy Awards Company “Smart Money” Grant - August 10 at 7:04 AM logoPluristem stock rises 2.5% on mid-stage clinical trial results - MarketWatch - July 27 at 6:35 AM logoNew Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery - July 27 at 6:35 AM logoPluristem stock rises 2.5% on mid-stage clinical trial results - July 27 at 6:35 AM logoThis new drug could help the US survive a nuclear meltdown - MarketWatch - July 15 at 7:46 AM logoA placenta cell medication could help the U.S. get through a nuclear meltdown - July 13 at 8:18 AM logoPluristem Therapeutics (PSTI) Advances Multinational Phase III Critical Limb Ischemia Study - - July 12 at 7:12 AM logoPluristem Therapeutics, Inc. (NASDAQ:PSTI) Receives Buy Rating from Maxim Group - July 10 at 11:38 AM logoBRIEF-Pluristem Therapeutics says on July 7, co entered into an at market issuance sales agreement - SEC Filing - July 9 at 3:38 PM logoPluristem Therapeutics (PSTI) to Present New Data from ARS study at RITN Conference - July 1 at 6:45 AM logoPluristem to Present New Data from ARS study at Radiology Conference in U.S. - June 29 at 7:36 AM logoZacks: Analysts Anticipate Pluristem Therapeutics, Inc. (PSTI) to Announce -$0.07 Earnings Per Share - June 27 at 8:10 PM logoPluristem Therapeutics, Inc. (PSTI) Upgraded by Maxim Group to Buy - June 19 at 4:28 PM logo Brokerages Expect Pluristem Therapeutics Inc. (PSTI) Will Announce Earnings of -$0.07 Per Share - June 1 at 6:32 PM logoPluristem Therapeutics Inc. (PSTI) Stock Rating Reaffirmed by HC Wainwright - May 29 at 8:32 AM logoPluristem Therapeutics Inc. (PSTI) Receives "Hold" Rating from Maxim Group - May 23 at 7:28 PM logoPluristem Provides Shareholder Update on Corporate and Clinical Developments - GlobeNewswire (press release) - May 22 at 9:29 AM logoPluristem Provides Shareholder Update on Corporate and Clinical Developments - May 22 at 9:29 AM logoPluristem reports 3Q loss - May 9 at 6:01 AM logo-$0.07 Earnings Per Share Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter - May 8 at 1:12 PM logoHC Wainwright Reiterates Buy Rating for Pluristem Therapeutics Inc. (PSTI) - May 7 at 10:02 AM logoPluristem Therapeutics Inc. (PSTI) Rating Reiterated by Maxim Group - May 7 at 7:34 AM



Pluristem Therapeutics (PSTI) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff